At a median follow-up of 4.9 years, the 5-year RFS rate was longer in the pembrolizumab group than in the placebo group in the intention-to-treat population (HR 0.61, 95% CI 0.51-0.72) and in those with PD-L1-positive tumours (HR 0.62, 95% CI 0.48-0.79). The gene discussed is CD274; the disease is neoplasm.